Notable
YL202 · BC
Primary completion pushed from Jul 30, 2026 to Jul 30, 2027
MediLink Therapeutics (Suzhou) Co., Ltd.Phase 2 NCT06439771 Registry history of NCT06439771 on ClinicalTrials.gov (opens the registry)
2 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 1 with a minor change only.
Primary completion pushed from Jul 30, 2026 to Jul 30, 2027
MediLink Therapeutics (Suzhou) Co., Ltd.Phase 2 NCT06439771 Registry history of NCT06439771 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Aug 31, 2026 to Jan 31, 2027
MediLink Therapeutics (Suzhou) Co., Ltd.Phase 2 NCT07202364 Registry history of NCT07202364 on ClinicalTrials.gov (opens the registry)
| Phase 1 | 4 | |
| Phase 1/2 | 8 | |
| Phase 2 | 4 | |
| Phase 3 | 7 |
Lung Cancer (9) · Non-Small Cell Lung Cancer (NSCLC) (6) · Breast Cancer (5) · Small Cell Lung Cancer (4) · Head & Neck Cancer (3) · Cervical Cancer (1) · Colorectal Cancer (1) · Esophageal Cancer (1) · Pancreatic Cancer (1) · Prostate Cancer (1)